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Synthetic Procedures
Molidustat was synthesized as reported 1, 2 . Synthetic procedures for GSK1278863, Vadadustat and AKB-6899 were modified from those reported. 3, 4 All chemicals used were reagent grade from Sigma Aldrich. Thin layer chromatography was performed using Merck aluminium plates (0.2 mm silica gel-60 F 254 ). After elution, TLC plates were visualized either under UV light or by staining with potassium permanganate or anisaldehyde followed by heating. Chromatographic separations were performed using a Teledyne Isco CombiFlash® Rf+ machine using either the silica gel or reverse phase pre-packed columns (ISCO). Selected infra red absorption frequencies are reported.
1 H NMR spectra were recorded in the Fourier Transform mode using a Bruker B-ACS 60 Ultrashield 400 plus spectrometer, operating at a nominal 1 H NMR frequency of 400 MHz, using the specified deuterated solvent. All spectra were processed using Topspin 3.0 software. Chemical shifts are reported in ppm and referenced to the residual solvent peak. Multiplicities in the NMR spectra are described as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad; coupling constants are reported in Hz (to the nearest 0.5 Hz).
Molidustat

1,2
Molidustat was synthesized as reported. 
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carabonyl]amino}acetic acid (Vadadustat)
To a solution of {[5-(3-chlorophenyl)-3-hydroxy pyridine-2-carbonyl] amino} acetic acid methyl ester, (50 mg, 0.16 mmol) in THF (2 mL) was added 1M LiOH (1.5 mL). The reaction mixture was stirred at room temperature for 2 h. The solution was acidified using 1M HCl (2 mL); the solvent was then removed in vacuo and the resulting solid suspended in CHCl 3 :isopropanol (1:1), and filtered. 
{[5-(3-Fluorophenyl)-3-hydroxypyridine-2-carabonyl] amino}acetic acid (AKB-6899)
To a solution of {[5-(3-fluorophenyl)-3-hydroxy pyridine-2-carbonyl] amino} acetic acid methyl ester, (50 mg, 0.16 mmol) in THF (2 mL) was added 1M LiOH (1.5 mL). The reaction mixture was stirred at room temperature for 2 h. The solution was acidified using 1M HCl (2 mL); the solvent was then removed in vacuo and the resulting solid suspended in CHCl 3 :isopropanol (1:1), and filtered. 
NMR experiments
Nuclear Magnetic Resonance (NMR) spectra were recorded using either a Bruker AVIII 600 MHz NMR spectrometer equipped with a BB-19 F/ 1 H Prodigy N 2 cryoprobe, or a Bruker AVIII 700 MHz NMR spectrometer equipped with a 5-mm inverse cryoprobe using 5 mm diameter NMR tubes (Norell) or 3 mm MATCH NMR tubes (Cortectnet). Data were processed using the Bruker 3.1 software. Prior to Fourier transformation, data were processed with a line broadening of 0.3 Hz. The catalytic domain of human PHD2 (residues 181-426) was used in all the protein NMR experiments.
For
1 H excitation sculpting suppression NMR experiments, the assay mixture contained 50 µM apo-PHD2 (obtained by EDTA treatment) supplemented with 200 µM Zn(II) and 500 µM of the compound to be studied buffered with 50 mM Tris-D 11 (pH 7.5) and 0.02 % NaN 3 in 90 % H 2 O and 10 % D 2 O. Spectra were typically obtained using 256 scans and a relaxation delay of 1 s. A 2 ms Sinc pulse was used for water suppression.
1 H Carr-Purcell-Meiboom-Gill (CPMG) NMR experiments, the assay mixtures contained 50 µM apo-PHD2 supplemented with 200 µM Zn(II) and 500 µM of the compound to be studied buffered with 50 mM Tris-D 11 (pH 7.5) and 0.02 % NaN 3 in 90 % H 2 O and 10 % D 2 O. Typical experimental parameters for CPMG NMR spectroscopy were as follows: total echo time, 40 ms; relaxation delay, 2 s; number of transients, 1024. The PROJECT-CPMG sequence (90°x−[τ−180°y−τ−90°y−τ−180°y−τ] n −acq) as described by Augilar et al. was used. 5 Water suppression was achieved by pre-saturation.
Water-Ligand Observed Gradient SpectroscopY (wLOGSY) experiments were conducted using the pulse sequence of Dalvit et al. 6 Unless stated, all experiments were at 277 K. Typical parameters were as follows: mixing time, 1 s; relaxation delay, 2 s; number of transients, 256. Solvent excitation was achieved using a 16 ms 180 degree selective rectangular shape pulse with 100% truncation level and 1000 points (Squa100.1000) set at the H 2 O frequency. Water suppression was achieved by a 2 ms Sinc (Sinc1.1000) pulse at the H 2 O frequency.
2OG displacement experiments were monitored by CPMG-edited 1 H NMR using a Bruker AV600 instrument. Samples contained 10 µM 2OG, 10 µM apo-PHD2 181-426 (if necessary) supplemented with 60 µM Zn(II) and increasing concentrations of the inhibitors from a DMSO-D 6 stock buffered with 50 mM Tris-D 11 (pH 7.5) and 0.02 % NaN 3 in 85 % H 2 O and 10 % D 2 O at 298 K. The PROJECT-CPMG sequence: (90°x−[τ−180°y−τ−90°y−τ−180°y−τ] n −acq), was applied. Typical experimental parameters were as follows: total echo time, 40 ms; relaxation delay, 2 s; number of transients, 264. Water suppression was achieved by presaturation.
13 C-CODD and 13 N-CODD displacement experiments, 1D Clean In-Phase (CLIP) HSQC with selective 13 C-inversion displacement experiments were conducted using a Bruker AV700 instrument. 3 mm MATCH NMR tubes were used (Cortecnet). All experiments were conducted at 298 K. The reporter CODD or NODD molecule was uniformly 13 C labelled on its prolyl-ring. 7 The CLIP-HSQC sequence was used for 1D HSQC experiments (without 13 C decoupling). 8 Relaxation delay was 2s. The 1 J CH was set to 160 Hz. A 6.8 ms Q3.1000 180 degree pulse was used and selective irradiation was applied at the selected chemical shift.
K D measurements were carried out as reported by Leung et al. using the PHD2.Zn(II) complex and 2OG as a reporter ligand. 9 Water relaxation experiments were conducted using a Bruker AV500 instrument using the PHD2.Mn(II) complex as reported by Leung et al.
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MALDI-TOF MS OGFOD1 hydroxylation assays
Recombinant human OGFOD1 was prepared as reported, 11 and stored at -80 °C in 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM DTT and 5% (w/v) glycerol after purification with immobilized metal affinity chromatography. Activity assays were performed by determining the extent of hydroxylation of a 20-residue fragment of human RPS23 containing amino acid residues 51-70 (H 2 N-VLEKVGVEAKQPNSAIRKCV-CONH 2 ) by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) using a Waters ® Micromass ® MALDI micro MX™ mass spectrometer and MassLynx™ 4.1 as described 12 . The optimised hydroxylation assay involved incubation of OGFOD1 (1 μM) with inhibitor (1 % v/v in DMSO) in the presence of Fe(II) (50 μM), 2OG (25 μM), L-ascorbic acid (100 μM) and RPS23 51-70 (25 μM) in HEPES (50 mM, pH 7.5) at 37 °C for 15 min. Reagent solution were made as previously reported. (64) Reactions were quenched with formic acid (1 % v/v). Samples were prepared by mixing reaction mixture (1 μL) with α-cyano-4-hydrocinnamic acid (CHCA) solution (water:acetonitrile 1:1) (1 μL). Dose-response was assessed in 8-point triplicates. Data were analysed using GraphPad Prism 5.04. 13 For enzyme production, the reported procedures were used. 13 E. coli BL21(DE3) cells transformed with pNIC28-His6-Ofd1 or pNIC28-His6-Tpa1pΔ2-20 were cultured to an OD600 of 0.6; recombinant protein production was induced through the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a concentration of 0.5 mM. The induced cultures were incubated overnight at 18°C with shaking, then harvested. The induced cells were suspended in 500 mM NaCl, 40 mM imidazole, 50 mM HEPES pH 7.5, sonicated, and the His-tagged protein was purified by nickel affinity chromatography. 13 Both Ofd1 and Tpa1p were bufferexchanged into 500 mM NaCl, 5% glycerol, 1 mM DTT, 50 mM HEPES pH 7.5 following immobilized metal affinity chromatography, flash-frozen and stored at -80°C. Enzyme assays consisted of Ofd1 (1 µM) or Tpa1p (2 µM) with 2OG (20 µM), L-ascorbic acid (100 µM), (NH 4 ) 2 Fe(SO 4 ) 2 (50 µM), RPS23 peptide (amino acid sequence AKGIVLEKVGVEAKQPNSAIRKCVRVQLIKNGKKITAF-CONH 2 ; 25 µM) and the relevant inhibitor (initially prepared in 10% DMSO, diluted to 1% DMSO in the reaction mixture) all in 50 mM HEPES pH 7.5. Reactions were quenched after 2 min (Ofd1) or 4 min (Tpa1p) by the addition of formic acid to a final concentration of 1%. The extent of hydroxylation was monitored by MALDI-TOF MS, and the IC 50 curve was fit to the data using Prism.
MALDI-TOF MS OFD1/TPA1p hydroxylation assays
LC-MS PHD2 hydroxylation assays
The PHD2 RF-MS RapidFire liquid chromatography mass spectrometry (RF-MS) assay monitors turnover of a C-terminal oxygenase dependent domain (CODD) peptide substrate DLDLEMLAPYIPMDDDFQL-CONH 2 and appearance of the hydroxylated peptide product (Pro564) in an endpoint type assay format (typical enzyme incubation time of 15 minutes). Tris(hydroxymethyl)aminomethane was from Fisher. Ferrous ammonium sulfate (FAS), 2-oxoglutarate (2OG) and L-ascorbic acid were from Sigma Aldrich; solutions of these were prepared freshly each day. All inhibition assays were carried out in 384-well polypropylene plates (Greiner Bio-One). PHD2 assays were performed in assay buffer (50 mM Tris.Cl pH 7.5, 50 mM NaCl). Titrations of compounds for IC 50 determinations (3-fold and 11-point IC 50 ) were prepared using an ECHO 550 acoustic dispenser (Labcyte) and dry dispensed into 384-well polypropylene assay plates. The final assay concentration of DMSO was kept constant at 0.5%. PHD2 protein was prepared at a concentration of 300 nM in assay buffer and 25 μl dispensed across each 384-well assay plate. The PHD2 solution was allowed to equilibrate with the inhibitors for 15 minutes at room temperature; the enzyme reaction then initiated by dispense of 25 μl of substrate (20 μM FAS, 200 μM L-ascorbic acid, 10 μM CODD peptide and 20 μM 2OG in the assay buffer. Enzyme reactions were allowed to proceed for 20 minutes at room temperature and the reaction terminated by addition of 10% formic acid (5 μl). Assay plates were then transferred to a RapidFire RF360 sampling robot (Agilent) connected to an Agilent 6530 accurate mass quadrupole-time-of-flight (Q-TOF) mass spectrometer. Assay samples were aspirated under vacuum and loaded onto a C4 solid phase extraction (SPE) cartridge. After loading the C4 SPE was washed with 0.1 % formic acid in water to remove non-volatile buffer salts and then peptide was eluted from the SPE with 85% acetonitrile, 15% water containing 0.1% formic acid onto the mass spectrometer. Peptide charge states were monitored in positive mode. Ion chromatogram data were extracted for the +2 charge state and peak area data integrated using RapidFire Integrator software (Agilent). % conversion of the CODD peptide substrate to the +16 hydroxylated peptide was calculated using the equation: % conversion = 100 x hydroxylated / (hydroxylated + non-hydroxylated peptide). IC 50 values were determined from non-linear regression plots using GraphPad prism.
LC-MS FIH hydroxylation assays
Tris(hydroxymethyl)aminomethane was from Fisher; all other reagents were from Sigma Aldrich and of the highest available purity. Ferrous ammonium sulphate (FAS) was prepared freshly every day as a 400 mM stock solution in 20 mM HCl, this was then diluted to 1 mM in deionized water. L-ascorbic acid (50 mM) and 2OG stock solutions (10 mM) were prepared freshly every day in deionized water as for the PHD2 assays. The synthetic consensus ankyrin peptide (HLEVVKLLLEAGADVNAQDK-CONH 2 ) 14 was synthesized by GL Biochem (Shanghai) Ltd and dissolved to 1 mM in deionized water. 20 μl FIH (100 nM) in the assay buffer (50 mM Tris.Cl pH 7.8, 50 mM NaCl) was preincubated for 15 minutes in the presence of the inhibitors and the enzyme reaction initiated by addition of 20 μl substrate (200 μM L-ascorbic acid, 20 μM Fe 2+ , 10 μM synthetic ankyrin peptide 14 and 20 μM 2OG). After 15 minutes the reaction was quenched by addition of 4 μl 10% formic acid and the reaction transferred to a RapidFire RF360 high throughput sampling robot. Samples were aspirated under vacuum onto a C4 Solid Phase Extraction (SPE) cartridge. After an aqueous washing step (0.1% formic acid in water), to remove non-volatile buffer components from the C4 SPE, peptide was eluted in an organic washing step (85% acetonitrile in water, 0.1% formic acid) and injected into an Agilent 6530 Q-TOF mass spectrometer. Ion chromatogram data was extracted for the non-hydroxylated peptide substrate and the hydroxylated peptide product; the peak area data for extracted ion chromatograms were integrated using RapidFire Integrator software. % conversion of substrate to product was calculated in Microsoft excel and IC 50 curves generated using Graphpad Prism.
Cell Culture and Immunoblotting
HeLa and RCC4 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Sigma Aldrich D6546-500ML) supplemented with 10% fetal bovine serum (Sigma Aldrich F7524-500ML), 4 mM L-glutamine (Sigma Aldrich G7513-100ML), 50 U/mL penicillin, and 50 μg/mL streptomycin (Sigma Aldrich P0781-100ML). Cells were seeded to reach 90-100% confluency prior to compound treatment. Cells were exposed to the inhibitor at a final concentration of 1% DMSO for 5-6 hours. For Fe(II) titration in the presence of inhibitors, ferric ammonium citrate was added to the cells for further 16 hours after 6 hours of incubation with the inhibitors.
Cells were harvested in urea/SDS buffer (6.7 M urea, 10 mM Tris-Cl pH 6.8, 10% glycerol, and1% SDS) supplemented with 1mM dithiothreitol following a phosphate-buffered saline (PBS) rinse. Cell extracts were analyzed with SDS-PAGE, electroblotted to polyvinylidene difluoride (PVDF) membrane (Millipore) and probed with the corresponding primary antibody for 1 hour at room temperature or overnight at 4 °C. The secondary antibody specific to primary antibody species conjugated with HRP were applied at room temperature for 1 hour. The antibodies used for immonoblotting were as follows: pan-anti-HIF-1α (clone 54, BD Transduction Laboratories™), anti-HIF-1α Hyp402 (catalogue number 07-1585, Merck Millipore), anti-HIF-1α Hyp564 (D43B5, Cell Signaling), anti-HIF-1α HyN803 (a generous gift from Lee et al. 15 ), PHD2 16 , PHD3 16 , and HRP-conjugated anti-β-actin (clone AC15, Abcam). Details of antibodies used are given in Tian et al. 17 Detection of signal was achieved using SuperSignal™ West Dura Extended Duration Substrate kit (Thermo Scientific 34075, unless otherwise stated) either with film or ChemiDoc TM MP (BIO-RAD) imaging system. Quantification of the immunobloting signal was performed with Image Lab TM software from BIO-RAD.
RT-qPCR assays
Cells were lysed using the TRI reagent ® (Sigma T9424). RNA was then extracted by phase separation following the manufacturer's protocol. Extracted RNA was treated with the RNasefree DNase I (DNA-free™ DNA Removal Kit, Applied Biosystems AM1906) to eliminate contaminating DNA. For reverse transcription, 1μg of DNase-treated RNA samples were used for cDNA synthesis using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific 4368814). RT-qPCR assays were performed with SYBR Green dye (Applied Biosystems 4385612) on a StepOnePlus thermocycler (Applied Biosystems). Quantitation of relative expression level was analyzed using the ΔΔC T method 18 with HPRT as a reference gene using; statistical analyses of the biological and technical repeats were calculated using StepOne Software (version 2.2.2). Sequences of primers used were: HPRT-forward 5′ GACCAGTCAACAGGGGACAT 3′, reverse 5′ AACACTTCGTGGGGTCCTTTTC 3′, BNIP3 -forward 5′ CGTTCCAGCCTCGGTTTCTATT 3′, reverse 5′ GAGCGAGGTGGGCTGTCAC 3′, CA9 -forward 5′ AGCACAGAAGGGGAACCAAAG 3′, reverse 5′ ATGAGCAGGACAGGACAGTTAC 3′, EPO -forward 5′ GAGCCCAGAAGGAAGCCATC 3′, reverse 5′ CGGAAAGTGTCAGCAGTGATTG 3′, PHD3 -forward 5′ CTGGTCCTCTACTGCGGGA 3′, reverse 5′ AGCCACCATTGCCTTAGACCTC 3′, SLC2A1 -forward 5′ GCCAAGAGTGTGCTAAAGAAGC 3′, reverse 5′ GCCGACTCTCTTCCTTCATCTC 3′, and VEGFA -forward 5′ GGCAGAATCATCACGAAGTGGT 3′, reverse 5′ GGCACACAGGATGGCTTGAA 3′.
Cell viability assays
Cell seeding and inhibitor treatments were performed in parallel in the same manner as used for the HRE reporter assay (see above). Resazurin (Sigma, R7017) was used for detection of cell viability at a final concentration of 10μg/ml. Cells were incubated with Resazurin at 37°C for 1-2 hours. Fluorescence signals were measured with an excitation wavelength of 544 nm and emission wavelength of 590 nm using a FLUOstar Omega Microplate Reader (BMG Labtech). in the FIH active site. In addition to electrostatic interactions with the metal and 2OG C-5 carboxylate binding pocket, Molidustat is positioned to form hydrophobic interactions between its triazole ring and Ile-281/Leu-188; and with Trp-296 and its metal coordinating rings. The observed GSK1278863 binding mode implies it is not positioned to form hydrophobic interactions with Ile-281/Leu-188, but to make electrostatic interactions with Lys-147/Thr-196; one of the GSK1278863 cyclohexyl rings projects into a hydrophobic region (Tyr-93/Phe-100). This binding mode apparently pushes the flexible residue Tyr-102 to new conformation relative to that in FIH structures with NOFD (PDB:1YCI) 19 or Daminozide (PDB:4AI8) 20 ; (the Tyr-102 side chain is disordered in the FIH-Molidustat complex GSK1278863). Note that the fit of the electron density map for the Nglycinamide and hydroxy-pyridine groups is good, whereas that for the chlorophenyl group is poorer, likely due to conformational flexibility of the chlorophenyl group. (B) Two major conformations were modelled, likely stabilized by weak hydrogen bonds with Arg-238 or interactions with Trp-296 in each case. Models for the side-chain orientation were based on 'pan-dataset' density analysis. 21 (C) Views from the FIH-Vadadustat crystal structure left (the Z-map contoured to 6σ) and, right, the PANDDA event map (2.60 Å resolution) with a 'Background Density Correction factor' (BDC) of 0.33 (contoured to 3σ), the latter implies two preferred confirmations for the chlorophenyl group. (D) Views from a crystal structure of PHD2 .Mn.Vadadustat the Fo-Fc OMIT map contoured to 3σ. 22 , and Vadadustat; PHD in complex with CCT6; NOG and HIF-1α CODD (PDB code 3HQR) 23 ; and OGFOD1 in complex with NOG (PDB code 4NHX) 11 . Analysis of the binding modes of Molidustat, GSK1278863, and Vadadustat reveals both inhibitors coordinate the active site metal in a bidentate manner. All three inhibitors coordinate the metal trans to Asp-201 and His-279; this contrasts with the structure with 2OG which coordinates the metal trans to Asp-201 and His-199. The coordination site trans to the distal histidine (His-279) is occupied by a water molecule in some FIH substrate complex structures. The metal coordination site trans to His-199 in the FIH Molidustat, GSK1278863 and Vadadustat structures is not occupied by a detectable ligand. In prolyl hydroxylases and structurally related 2OG oxygenases, however, 2OG coordinates the metal trans to the distal histidine and acidic metal binding residue (His-313 and Asp-315) 24 . Overlay of the FIH.Zn.Molidustat complex structure with the FIH.Fe.2OG (PDB 2Y0I) and PHD2.Mn.NOG (PDB 3HQR) complex structures reveals that the binding mode of Molidustat more closely reassembles the active site PHD2-2OG binding rather than FIH-2OG binding. 1 H CPMG NMR screening of an equimolar enzyme-inhibitor mixture (50 µM) of GSK1278863 and PHD2. The addition of GSK1278863 to PHD2 leads to a partial reduction in the intensity of the peaks of GSK1278863 with an equimolar enzyme-inhibitor mixture, characteristic of moderate to strong binding. Red curves: GSK1278863 and PHD2; blue curves: GSK1278863 alone. S11 . In vitro PHD isoform selectivity profiling of PHD inhibitors. Inhibition of PHD inhibitors against human PHD1-3 as assayed by MALDI-TOF MS (the protocol is described in Chan et al. 25 ). Eight concentrations were used to obtained dose-response curve for each compound. Data points presented in the graph are mean with standard deviation, n=3. IC 50 values (listed in Supplemental Table S3 ) were calculated using GraphPad Prism® 5.04. Fig. S12 . In vitro OGFOD1 selectivity profiling of PHD inhibitors. Inhibition of PHD inhibitors against human OGFOD1 as assayed by MALDI-TOF MS (the protocol is described in the Supplemental Materials and Methods section). 11, 13 No enzyme and DMSO controls were used for the normalisation of RPS23 peptide hydroxylation. Eight concentrations were used to obtained dose-response curve for each compound. Data points presented in the graph are means with standard deviation, n=3. IC 50 values (listed in Table 2 ) were calculated using GraphPad Prism® 5.04. Table 2 ) were calculated using GraphPad Prism® 5.04. Table 2 ) were calculated using GraphPad Prism® 5.04. Abbreviation: BIW-twice weekly; TIW-three times weekly; QW-once weekly; BID-twice daily; CKD-chronic kidney disease; NDD-non-dialysis dependent; ESAErythropoiesis-stimulating agent; Hb-hemoglobin.
